Template:Rifampin isoniazid: Difference between revisions
Jump to navigation
Jump to search
(Created page with "{| style="margin: 0 0 3em 3em; border: 1px solid #696969; float: right; width:20em" cellpadding="0" cellspacing="0"; | style="padding: 0 5px; font-size: 100%; background:#6969...") |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 2: | Line 2: | ||
| style="padding: 0 5px; font-size: 100%; background:#696969" align=center | <span style="color:WHITE;"> '''[[Rifampin isoniazid|Rifampin isoniazid]]'''</span> | | style="padding: 0 5px; font-size: 100%; background:#696969" align=center | <span style="color:WHITE;"> '''[[Rifampin isoniazid|Rifampin isoniazid]]'''</span> | ||
|- | |- | ||
! style="padding: 0 5px; font-size: 85%; background:WHITE" align=left | FDA Package Insert ( | ! style="padding: 0 5px; font-size: 85%; background:WHITE" align=left | FDA Package Insert (RIFAMATE<sup>®</sup>) | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid description|Description]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid description|Description]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid clinical pharmacology|Clinical Pharmacology]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid clinical pharmacology|Clinical Pharmacology]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid indications and usage|Indications and Usage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid indications and usage|Indications and Usage]] | ||
| Line 19: | Line 17: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid overdosage|Overdosage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid overdosage|Overdosage]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid dosage and administration|Dosage and Administration]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid how supplied|How Supplied]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left |[[Rifampin isoniazid how supplied|How Supplied]] | ||